Molbio Diagnostics raised ₹281.5 crore from 33 anchor investors at ₹807 a share, the top of the IPO price band. Goldman Sachs, BlackRock and nine domestic fund houses participated. The IPO opens August 10.
Molbio Diagnostics locked in ₹281.5 crore from anchor investors at the top of its price band, a sign of demand ahead of an IPO that could value the point-of-care diagnostics company at roughly ₹9,300 crore.
The company allotted 34.88 lakh shares at ₹807 apiece to 33 anchor investors, the BSE circular showed. Goldman Sachs, BlackRock Global Funds, Mirae Asset, ICICI Prudential Mutual Fund, Kotak Mutual Fund, Nippon India Mutual Fund, Tata Mutual Fund, WhiteOak Capital, Bajaj Life Insurance and HDFC Life Insurance were among the largest participants.
Domestic mutual funds took 23.54 lakh shares, or 67.51% of the anchor book, through 19 schemes across nine fund houses.
The IPO combines a fresh issue of shares worth up to ₹200 crore with an offer for sale of up to 91.66 lakh equity shares from existing holders. Selling shareholders include Exxora Trading LLP, Dr Chandrasekhar Bhaskaran Nair, India Business Excellence Fund III, Gopalkrishna Mangalore Kini, J Guru Dutt and several others.
Molbio plans to use ₹106 crore of the fresh proceeds for infrastructure tied to an R&D facility, a Centre of Excellence and connected office space. Another ₹72 crore will go toward plant, machinery and equipment for its Goa Unit I, Goa Unit II and Visakhapatnam unit. The balance will cover general corporate purposes.
The price band runs ₹768-807 per share. Public subscription opens August 10 and closes August 12. Listing on the BSE and NSE is scheduled for August 17.
Incorporated in 2000 and backed by Temasek and Motilal Oswal Private Equity, Molbio Diagnostics offers molecular testing for 30 diseases including tuberculosis, COVID, HIV, HPV and Hepatitis B and C. Its Truenat platform, patented in more than 100 countries, is a battery-operated point-of-care PCR system designed for resource-limited settings. The company operates six manufacturing facilities in India and, as of March 31, 2026, had installed capacity of 5,400 devices per year and 3.9 crore test kits annually.
Revenue from operations hit ₹1,445 crore in fiscal 2026, with profit at ₹164 crore.
Kotak Mahindra Capital Company, IIFL Capital Services, Jefferies India and Motilal Oswal Investment Advisors are managing the issue.
Drafted by a large language model from the source reporting linked above, then screened by automated publishing checks. It is not read by a journalist before publication. Some articles cite our Alpha Score. Verify prices and figures against the original source. Educational coverage, not personalized advice.